restriction

WASHINGTON — The Supreme Court is leaving access to a widely used abortion pill untouched until at least Thursday, while the justices consider whether to allow restrictions on the drug, mifepristone, to take effect.

Justice Samuel A. Alito Jr.’s order Monday allows women seeking abortions to continue obtaining the pill at pharmacies or through the mail, without an in-person visit to a doctor. It prevents restrictions on mifepristone imposed by a federal appeals court from taking effect for the time being.

The court is dealing with its latest abortion controversy four years after its conservative majority overturned Roe vs. Wade and allowed more than a dozen states to effectively ban abortion outright.

The case before the court stems from a lawsuit Louisiana filed to roll back the Food and Drug Administration’s rules on how mifepristone can be prescribed. The state claims the policy undermines the ban there, and it questions the safety of the drug, which was first approved in 2000 and has repeatedly been deemed safe and effective by FDA scientists.

Lower courts concluded that Louisiana is likely to prevail, and a three-judge panel of the U.S. 5th Circuit Court of Appeals ruled that mail access and telehealth visits should be suspended while the case plays out.

The drug is most often used for abortion in combination with another drug, misoprostol. Medication abortions accounted for nearly two-thirds of all abortions in the U.S. in 2023, the last year for which statistics are available.

The current dispute is similar to one that reached the court three years ago.

Lower courts then also sought to restrict access to mifepristone, in a case brought by physicians who oppose abortion. They filed suit in the months after the court overturned Roe.

The Supreme Court blocked the 5th Circuit ruling from taking effect over the dissenting votes of Alito and Justice Clarence Thomas. Then, in 2024, the high court unanimously dismissed the doctors’ suit, reasoning they did not have the legal right, or standing, to sue.

In the current dispute, mainstream medical groups, the pharmaceutical industry and Democratic members of Congress have weighed in cautioning the court against limiting access to the drug. Pharmaceutical companies said a ruling for abortion opponents would upend the drug approval process.

The FDA has eased a number of restrictions initially placed on the drug, including who can prescribe it, how it is dispensed and what kinds of safety complications must be reported.

Despite those determinations, abortion opponents have been challenging the safety of mifepristone for more than 25 years. They have filed a series of petitions and lawsuits against the agency, generally alleging that it violated federal law by overlooking safety issues with the pill.

President Trump’s administration has been unusually quiet at the Supreme Court. It declined to file a written brief recommending what the court should do, even though federal regulations are at issue.

The case puts Trump’s Republican administration in a difficult place. Trump has relied on the political support of antiabortion groups but has also seen ballot question and poll results that show Americans generally support abortion rights.

Both sides took the silence as an implicit endorsement of the appellate ruling. Alito is both the justice in charge of handling emergency appeals from Louisiana and the author of the 2022 decision that declared abortion is not a constitutional right and returned the issue to the states.

Sherman, Mulvihill and Perrone write for the Associated Press. Mulvihill reported from Haddonfield, N.J.

April 16 (UPI) — The Trump administration on Thursday announced visa restrictions on 26 people across the Western Hemisphere as the State Department unveiled a “significant expansion” of an existing policy to deny entry to those accused of working with U.S. adversaries to undermine Washington’s interests in the region.

Those blacklisted were not identified in the State Department release, which said they were being punished for destabilizing U.S. regional security efforts, undermining U.S. economic interests, conducting influence operations targeting the sovereignty and stability of nations in the region or enabling adversaries to acquire or control key assets and strategic resources in the hemisphere.

“President Trump’s National Security Strategy makes clear: this Administration will deny adversarial powers the ability to own or control vital assets or threaten the security and prosperity of the United States in our region,” a State Department spokesperson said.

“The Department of State is working to advance American leadership in our hemisphere, protect our homeland and ensure access to vital routes and areas throughout our region.”

The blacklisting was permitted as the State Department said it was announcing “a significant expansion” of an existing visa restriction policy, one first announced in early September, permitting the Trump administration to deny visas to Central American nationals accused of undermining the rule of law in the region on behalf of China.

The move comes as the Trump administration seeks to expand its influence in the Western Hemisphere. Under what some administration officials have called the “Donroe Doctrine,” Trump has sought to reassert U.S. dominance in the region in the Western Hemispher and push back on foreign influence, invoking a modern corollary to the Monroe Doctrine of the 1820s.

That initial policy specifically targeted those in Central America who collaborated with the Chinese Communist Party, while the expansion includes anyone in the Western Hemisphere who aids any of the United States’ adversaries.

China protested the earlier version of the policy in November. In a statement from its embassy in Washington, Beijing said the United States imposed visa restrictions on nationals from Panama and other Central American nations over their ties to China.

“Turning visas into political leverage runs against #UN Charter and the principles of sovereign equality and non-interference,” the embassy said. “Central America is no one’s backyard.”